Upfront News

This is selected news for Upfront, which is filed under Sectors / Healthtech. There are 66 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
9/22/2022 GSK and Spero Therapeutics Announce Exclusive License
The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries Spero Therapeutics receives $66 million upfront, with potential for future milestone payments, and tiered royalties. GSK to purchase $9 million in shares of Spero common stock LONDON and CAMBRIDGE, Mass., Sept ...
Globe Newswire
9/22/2022 GSK and Spero Therapeutics Announce Exclusive License
The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries Spero Therapeutics receives $66 million upfront, with potential for future milestone payments, and tiered royalties. GSK to purchase $9 million in shares of Spero common stock LONDON and CAMBRIDGE, Mass., Sept ...
Globe Newswire
9/22/2022 Undeterred by FDA setback, GSK snaps up Spero antibiotic
Undeterred by FDA setback, GSK snaps up Spero antibiotic GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults with complicated urinary tract infections (cUTI). The big pharma ...
Pharma Phorum
9/20/2022 Basilea announces acquisition of rights for oncology asset
Upfront and near-term milestone payments of USD 14 million Additional milestone payments of approximately USD 320 million and tiered royalties on net sales Second oncology transaction as part of strategic refocusing on anti-infectives Full-year 2022 revenue guidance increased, resulting in improved expected operating result and operating cash ...
Globe Newswire
9/20/2022 Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
... ovarian cancer, peripheral T cell lymphoma and acute myeloid leukemia. Under the terms of the agreement, Puma will assume sole responsibility for the global development and commercialization of alisertib. Takeda will receive an upfront license fee of $7 million and is eligible to receive potential future milestone payments of up ...
Business Wire
9/19/2022 McKesson Signs Agreement to Acquire Rx Savings Solutions PR Newswire
9/19/2022 McKesson Signs Agreement to Acquire Rx Savings Solutions | Business Wire Business Wire
9/19/2022 McKesson Signs Agreement to Acquire Rx Savings Solutions Business Wire
9/15/2022 Vetster Named “Pet App of the Year” In 2022 Pet Independent Innovation Awards Program - PR Web PRWeb
9/14/2022 Patient Engagement Platform Upfront Closes $10.5 Million In Funding pulse2.com
9/14/2022 Global Generic Drugs Market to Reach $482.5 Billion by 2027 at a CAGR of 7% PR Newswire
9/13/2022 Main Street Monday – Veteran Documentation for $0 Upfront Fee on 7(a) Loans in FY23 colemanreport.com
9/13/2022 METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi Business Wire
9/12/2022 Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab Globe Newswire
9/12/2022 AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million Globe Newswire
9/9/2022 Global Genomics Partnering Deals Analysis Report 2022: Company A-Z, Headline Value, Upfront, Milestone and Royalties, Stage of Development, Deal Components, Specific Therapy and Technology Target PR Newswire
9/9/2022 This Recruitment Agency Matches Medical Witnesses With Legal Firms & Insurers PRSync
9/9/2022 Global Pediatrics Partnering Report 2022: Partnering in the Research, Development and Commercialization of Pediatrics Technologies and Products PR Newswire
9/9/2022 Global Gynecology Partnering Report 2022: Deal Trends, Key Players, Top Deal Values, Upfront Payments, Milestones and Royalties, Value of Current Deals PR Newswire
9/9/2022 Global Gynecology Partnering Report 2022: Deal Trends, Key Players, Top Deal Values, Upfront Payments, Milestones and Royalties, Value of Current Deals Yahoo News
9/8/2022 LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million PR Newswire
9/8/2022 Basilea announces sale of preclinical oncology program to Globe Newswire
9/8/2022 Arcutis Announces Acquisition of Ducentis BioTherapeutics Globe Newswire
9/8/2022 Generic Drugs Rapid Patent Globe Newswire
9/8/2022 Arcutis Announces Acquisition of Ducentis BioTherapeutics Globe Newswire